“On another note- Gilead purchased Immunomedics knowing they failed and the numbers were much worse than Leronlimab.”
False. Gilead purchased Immunomedics for $21 billion, a 108% premium, about 6 months after Trodelvy was approved for TNBC by the FDA. Trodelvy had sales of $100 million in the 3rd quarter of 2021. Trodelvy’s trial was much more robust than any cancer trial CYDY has run so far.
fda really put the screws to cydy no wonder they went to brazil for their covid trial.looking like we should get some results soon and i have a hunch they will be vastly improved.
News 
Market Data 
Discover 
